Trial Profile
A multicenter, randomized, double-blind, placebo-controlled efficacy study comparing 4 weeks of treatment with esomeprazole 20 mg qd to placebo qd in patients with heartburn and sleep disturbances associated with gastroesophageal reflux disease (GERD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Mar 2015
Price :
$35
*
At a glance
- Drugs Esomeprazole (Primary)
- Indications Gastro-oesophageal reflux; Heartburn; Sleep disorders
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 28 Apr 2010 Results published in Alimentary Pharmacology and Therapeutics.
- 04 Jun 2009 Results presented at Digestive Disease Week 2009.
- 02 Jun 2009 Primary endpoint 'Resolution of night time heartburn' has been met.